Medicaid coverage of Janus kinase inhibitors for alopecia areata treatment

1. Pharmacoeconomic Review Report: Baricitinib (Olumiant): (Eli Lilly Canada Inc.): Indication: For Use in Combination with Methotrexate (MTX) for the Treatment of Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Have Responded Inadequately to One or More Disease-Modifying Antirheumatic Drugs (DMARDs). Baricitinib May Also Be Used as Monotherapy in Cases of Intolerance to MTX. Canadian Agency for Drugs and Technologies in Health; 2019. https://www.ncbi.nlm.nih.gov/books/NBK549720/

2. Petitt CE, Kiracofe E, Adamson A, Barbieri JS. Prior authorizations in dermatology and impact on patient care: An updated survey of US dermatology providers and staff by the American Academy of Dermatology. Dermatol Online J. 2021;27(1). doi:10.5070/D3271052021. PMID:33560787

3. Sy N, Mastacouris N, Strunk A, Garg A. Overall and Racial and Ethnic Subgroup Prevalences of Alopecia Areata, Alopecia Totalis, and Alopecia Universalis. JAMA Dermatol. 2023;159(4):419-423. doi:10.1001/jamadermatol.2023.0016. PMID:36857044

4. Marks DH, Penzi LR, Ibler E, et al. The Medical and Psychosocial Associations of Alopecia: Recognizing Hair Loss as More Than a Cosmetic Concern. Am J Clin Dermatol. 2019;20(2):195-200. doi:10.1007/s40257-018-0405-2. PMID:30390206

5. Nohria A, Zhang YC, Desai D, et al. Real-world experience quantifying access to JAK inhibitor care for alopecia areata patients: a patient-centered survey study. Int J Womens Dermatol. 2024;10(2):e145. doi:10.1097/JW9.0000000000000145. PMID:38606145